

· Letter ·

## Chemical Constituents in Charred *Sanguisorbae Radix*

SUN Li-li<sup>1\*</sup>, ZHONG Ying<sup>2</sup>, XIA Hong-min<sup>2</sup>, ZHOU Qian<sup>1</sup>, LV Jia<sup>2</sup>

1. Shandong Academy of Chinese Medicine, Jinan 250014, China

2. Key Laboratory for Modern Medicine and Technology of Shandong Province, Institut of Materia Medica, Shandong Academy of Medical Sciences, Jinan 250062, China

**Abstracts:** **Objective** To study the chemical constituents in the effective fractions of charred *Sanguisorbae Radix*. **Methods** The compounds were isolated and purified by column chromatography and their structures were identified on the basis of physicochemical properties and spectral analysis. **Results** Five compounds were isolated and identified as 3 $\beta$ -hydroxy-28-norurs-17,19,21-trien (**1**), 3 $\beta$ -hydroxy-28-norurs-12,17-dien (**2**), 3 $\beta$ ,19 $\alpha$ -dihydroxyurs-13(18)-en-28-oic acid (**3**), 3 $\beta$ -[( $\alpha$ -L-arabinopyranosyl)oxy]-28-norurs-12,17-dien (**4**), and pomolic acid (**5**). **Conclusion** Compounds **1**, **3**, and **4** are novel compounds belong to triterpenoids and triterpenoid saponins, named as sanguisorbigenins Z, Y<sub>1</sub>, and Y<sub>2</sub>, respectively.

**Key words:** charred *Sanguisorbae Radix*; pomolic acid; sanguisorbigenin Y<sub>1</sub>; sanguisorbigenin Y<sub>2</sub>; sanguisorbigenin Z

**DOI:** 10.7501/j.issn.1674-6384.2013.01.001

### Introduction

Garden burnet root is the dried root of *Sanguisorba officinalis* L. or *S. officinalis* L. var. *longifolia* (Bert.) Yu et Li (Rosaceae) (Pharmacopoeia Committee of P. R. China, 2010). It distributes widely in China. It has shown some therapeutic activities, such as cooling blood and detoxification. Currently, *Sanguisorbae Radix* (SR) and charred *Sanguisorbae Radix* (CSR) are the most commonly-used processed products in clinic (The Traditional Chinese Medicine Preparation Standards, 1988). After being charred, SR became CSR, and its hemostatic effect was enhanced, and its main efficacy was changed to convergence bleeding (Guo, Jia, and Xu, 2001). In order to explore the material basis for the enhanced role to stop bleeding, we conducted a study on the chemical compositions in the EtOAc and CHCl<sub>3</sub> fractions then identified them as the effective fractions with hemostatic activity. In preliminary study, we have already isolated and purified 11 compounds from EtOAc fraction and six compounds from CHCl<sub>3</sub> fraction (Xia *et al*, 2010a; 2010b). To further study the material basis of

hemostatic activity of CSR, we continued to study the chemical constituents in CHCl<sub>3</sub> fraction.

By column chromatography, preparative TLC, and other means, five compounds were isolated and identified as 3 $\beta$ -hydroxy-28-norurs-17,19,21-trien (**1**), 3 $\beta$ -hydroxy-28-norurs-12,17-dien (**2**), 3 $\beta$ ,19 $\alpha$ -dihydroxyurs-13(18)-en-28-oic acid (**3**), 3 $\beta$ -[( $\alpha$ -L-arabinopyranosyl)oxy]-28-norurs-12,17-dien (**4**), and pomolic acid (**5**). Compounds **1**, **3**, and **4** are novel compounds belong to triterpenoids and triterpenoid saponins, named as sanguisorbigenins Z, Y<sub>1</sub>, and Y<sub>2</sub>, respectively. By studying the influence of processing on the content of sanguisorbigenin Z, we found that it could be an index component to control the quality and processing degree of CSR (Dai *et al*, 2011). We also have confirmed that sanguisorbigenins Y<sub>1</sub> and Y<sub>2</sub> showed anticancer activity (Sun *et al*, 2011a; 2011b).

### Materials and methods

#### Apparatus and reagents

Melting points were determined using a Stuart Smp3

\* Corresponding author: Sun LL Address: No.7 Yanzishanxi Road, Ji'nan 250014, China  
Tel: +86-531-8294 9829 E-mail: xingerx@163.com

Received: October 18, 2012; Revised: November 26, 2012; Accepted: December 5, 2012

Fund: National Natural Science Foundation of China—Study on the Mechanism of Diyutan Processing (30772786)

Melting Point Apparatus. MS spectra were recorded with Agilent Trap VL Mass Spectrometer. IR spectra were obtained with a Nicolet Avatar—330 FT-IR. UV spectra were measured on a Shimadzu UV—2201 UV-Vis Spectrophotometer.  $^1\text{H-NMR}$  (400 MHz) and  $^{13}\text{C-NMR}$  (100 MHz) spectra were recorded with Bruker Advanced 400 NMR Spectrometers.

Column chromatography was performed with silica gel (Qingdao Haiyang Chemical Co., Ltd., China). Ethanol, (60—90) °C petroleum ether, acetone, chloroform, and other reagents were of analytical grade.

#### Plant materials

*Sanguisorbae Radix* was collected from Longxi in Gansu province (China), identified by Prof. LIN Hui-bin in Shandong Academy of Chinese Medicine, and processed to obtain charred *Sanguisorbae Radix*. A voucher specimen was deposited in the Unit for Research of Processing in Shandong Academy of Chinese Medicine.

#### Extraction and isolation

The dried and powdered CSR (12 kg) was extracted with 80% ethanol (120 L) twice (2 h each time) under reflux. The extract was combined and concentrated under reduced pressure, and was subsequently partitioned successively with petroleum ether,  $\text{CHCl}_3$ , EtOAc, and *n*-butanol. The  $\text{CHCl}_3$  fraction (214.8 g) was subjected to column chromatography on silica gel (1200 g, 160—200 mesh) eluted with petroleum ether-acetone (100:0→5:5).

Compounds **1** (84.6 mg) and **2** (281.2 mg) were obtained from the petroleum ether-acetone (95:5) fraction. Compound **3** (15.9 mg) was obtained from the petroleum ether-acetone (8:2) fraction. Compound **4** (22.9 mg) was obtained from the petroleum ether-acetone (75:25) fraction.

Based on TLC analysis, petroleum ether-acetone (8:2) and petroleum ether-acetone (75:25) fractions were emerged and then were further separated on a silica gel H eluting with  $\text{CHCl}_3$ -MeOH. Compound **5** (17.3 mg) was obtained eluting with  $\text{CHCl}_3$ -MeOH (93:7).

### Results and discussion

Compound **1**: white crystal (EtOAc), mp 244—246 °C.  $[\alpha]_{\text{D}}^{20} + 0.39^\circ$  (*c* 0.054, MeOH). UV  $\lambda_{\text{max}}^{\text{MeOH}}$  (nm): 215.7, 273.0. IR  $\nu_{\text{max}}^{\text{KBr}}$  ( $\text{cm}^{-1}$ ): 3471 (OH), 2937, 1468, 1449 (C=C, benzene ring). HR-ESI-MS (negative)

$m/z$ : 407.3315  $[\text{M} - \text{H}]^+$  ( $\text{C}_{29}\text{H}_{43}\text{O}$ , calcd. 407.3308).  $^1\text{H-NMR}$  (400 MHz,  $\text{C}_5\text{D}_5\text{N}$ )  $\delta$ : 0.94 (3H, s, 25- $\text{CH}_3$ ), 0.95 (3H, s, 27- $\text{CH}_3$ ), 1.03 (3H, s, 26- $\text{CH}_3$ ), 1.08 (3H, s, 24- $\text{CH}_3$ ), 1.26 (3H, s, 23- $\text{CH}_3$ ), 2.21 (3H, s, 30- $\text{CH}_3$ ), 2.23 (3H, s, 29- $\text{CH}_3$ ), 6.94 (1H, d,  $J = 7.6$  Hz, H-22), 7.01 (1H, d,  $J = 7.6$  Hz, H-21), 3.49 (1H, m, H-3). The  $^{13}\text{C-NMR}$  spectrum of compound **1** (Table 1) exhibited seven tertiary methyl groups, four quaternary olefinic carbons, two olefinic methines, and one hydroxyl methine. The  $^1\text{H-NMR}$  and  $^{13}\text{C-NMR}$  spectral data of compound **1** showed two *o*-positioned aromatic protons  $\delta_{\text{H}}$  6.94 (1H, d,  $J = 7.6$  Hz, H-22), 7.01 (1H, d,  $J = 7.6$  Hz, H-21), with six typical aromatic carbon signals at  $\delta_{\text{C}}$  136.0, 140.0, 135.9, 134.8, 127.0, and 126.3. By analyzing the 2D NMR spectra, compound **1** was revealed to have a 28-nor-ursane skeleton. HMBC correlations are observed from Me-29 to quaternary C-18 and 20, as well as from Me-30 to quaternary C-19 and 21. One of the two aromatic protons H-21 shows HMBC correlations with quaternary C-17, C-19, and Me-30. H-22 shows HMBC correlations with quaternary C-18, C-20, and methylene C-16. Through analyzing HSQC and HMBC, the hydroxymethine proton was assigned as H-3. NOESY correlation between H-3 and H<sub>3</sub>-23/H-5 indicated the  $\alpha$ -orientation of H-3. Therefore, the structure of compound **1** was assigned as 3 $\beta$ -hydroxy-28-norurs-17,19,21-trien. It is a new compound named sanguisorbigenin Z (Fig. 1).

Compound **2**: white crystal (EtOAc), mp 205—207 °C.  $[\alpha]_{\text{D}}^{20} + 0.11^\circ$  (*c* 0.102, MeOH). UV  $\lambda_{\text{max}}^{\text{MeOH}}$  (nm): 300.0, 243.9, 236.6. IR  $\nu_{\text{max}}^{\text{KBr}}$  ( $\text{cm}^{-1}$ ): 3464 (OH), 2938 (saturated C-H), 1452, 1386 ( $\text{CH}_3$ ). HR-ESI-MS (negative)  $m/z$ : 409.3474  $[\text{M} - \text{H}]^-$  ( $\text{C}_{29}\text{H}_{45}\text{O}$ , calcd. 409.3465).  $^1\text{H-NMR}$  (400 MHz,  $\text{C}_5\text{D}_5\text{N}$ )  $\delta$ : 0.95 (3H, s, 26- $\text{CH}_3$ ), 1.02 (3H, s, 25- $\text{CH}_3$ ), 1.05 (3H, s, 27- $\text{CH}_3$ ), 1.08 (3H, s, 24- $\text{CH}_3$ ), 1.27 (3H, s, 23- $\text{CH}_3$ ), 0.88 (3H, d,  $J = 6.9$  Hz, 29- $\text{CH}_3$ ), 0.96 (3H, d,  $J = 7.9$  Hz, 30- $\text{CH}_3$ ), 3.50 (1H, m, H-3), 5.71 (1H, brs, H-12). The  $^{13}\text{C-NMR}$  spectrum of compound **2** (Table 1) exhibited seven methyl carbons, three quaternary olefinic carbons, one olefinic methane, and one hydroxyl methine. The  $^1\text{H-NMR}$  and  $^{13}\text{C-NMR}$  spectral data showed an olefinic proton [ $\delta$  5.71 (1H, brs, H-12)], with four typical olefinic carbon signals at  $\delta_{\text{C}}$  117.5, 137.6, 128.9, and 133.5. By analyzing the 2D NMR spectra, compound **2** was revealed to have a 28-nor-ursane

skeleton. HMBC correlations were observed from H-11 to an olefinic methine C-12 and a quaternary olefinic carbon C-13, from Me-27 to a quaternary olefinic carbon C-13, from Me-29 to a quaternary olefinic carbon C-18, as well as from H-15 to a quaternary olefinic carbon C-17. Through analyzing HSQC and HMBC, the hydroxymethine proton was assigned as H-3. NOESY correlation between H-3 and H<sub>3</sub>-23/H-5 indicated the  $\alpha$ -orientation of H-3. Therefore, compound **2** was assigned as 3 $\beta$ -hydroxyl-28-norurs-12,17-dien.

Compound **3**: white powder (EtOAc), mp 257—260 °C,  $[\alpha]_D^{20} + 57.7^\circ$  (*c* 0.017, MeOH). UV  $\lambda_{\max}^{\text{MeOH}}$  (nm): 287.2, 243.7, 236.6. IR  $\nu_{\max}^{\text{KBr}}$  (cm<sup>-1</sup>): 3421 (OH), 2938 (saturated C-H), 1450, 1388 (CH<sub>3</sub>), 1065 (C-O). HR-ESI-MS (negative) *m/z*: 541.3891 [M - H]<sup>-</sup> (C<sub>34</sub>H<sub>53</sub>O<sub>5</sub>, calcd. 541.3888). <sup>1</sup>H-NMR (400 MHz, C<sub>5</sub>D<sub>5</sub>N)  $\delta$ : 0.91 (3H, s, 26-CH<sub>3</sub>), 0.94 (3H, s, 25-CH<sub>3</sub>), 0.94 (3H, s, 27-CH<sub>3</sub>), 1.05 (3H, s, 24-CH<sub>3</sub>), 1.07 (3H, s, 23-CH<sub>3</sub>), 0.85 (3H, d, *J* = 6.1 Hz, 29-CH<sub>3</sub>), 0.96 (3H, d, *J* = 5.9 Hz, 30-CH<sub>3</sub>), 3.30 (1H, m, H-3), 5.68 (1H, brs, H-12), 5.59 (1H, d, *J* = 2.0 Hz, Ara-H-1'). The <sup>13</sup>C-NMR spectrum of compound **3** (Table 1) exhibited seven methyl carbons, three quaternary olefinic carbons, one olefinic methine, one oxymethine, and one anomeric carbon. The <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra showed an olefinic proton [ $\delta_{\text{H}}$  5.68 (1H, brs, H-12)], with four typical olefinic carbon signals at  $\delta_{\text{C}}$  117.4, 137.6, 128.9, and 133.5. By analyzing the 2D NMR spectra, the aglycone of compound **3** is revealed to have a 28-nor-ursane skeleton. HMBC correlations were observed from H-11 to an olefinic methine C-12 and a quaternary olefinic carbon C-13, from Me-27 to a quaternary olefinic carbon C-13, from Me-29 to a quaternary olefinic carbon C-18, as well as from H-15 to a quaternary olefinic carbon C-17. Through analyzing HSQC and HMBC, the hydroxymethine proton was assigned as H-3. NOESY correlation between H-3 and H<sub>3</sub>-23/H-5 indicated the  $\alpha$ -orientation of H-3. Based on the above evidences, the aglycone of compound **3** was elucidated as 3 $\beta$ -hydroxy-28-norurs-12,17-dien, same as compound **2**. The <sup>1</sup>H-NMR spectrum showed one anomeric proton resonating at  $\delta_{\text{H}}$  5.59, which was correlated with  $\delta_{\text{C}}$  87.3 from the HMQC spectrum. The difference between compounds **2** and **3** was that the C-3 signal of compound **3** shifted from  $\delta$  78.2 to  $\delta$  87.3. HMBC correlations were also observed

from an anomeric proton Ara-H-1' to the oxymethine carbon C-3. The coupling constant of Ara-H-1' (*d*, *J* = 2.0 Hz) confirmed the  $\alpha$ -glycosidic linkage for the *L*-arabinose units. The <sup>13</sup>C-NMR spectrum confirmed that the *L*-arabinose was  $\alpha$ -*L*-arabinofuranoside. After acid hydrolysis, the sugar units were confirmed to be *L*-arabinose by gas chromatographic (GC) analysis. Therefore, compound **3** was assigned as 3 $\beta$ -[( $\alpha$ -*L*-arabinofuranosyl)oxy]-28-norurs-12,17-dien. It is a new compound named as sanguisorbin Y<sub>1</sub> (Fig. 1).

Compound **4**: white crystal (EtOAc),  $[\alpha]_D^{20} + 0.44^\circ$  (*c* 0.132, MeOH). UV  $\lambda_{\max}^{\text{MeOH}}$  (nm): 242.9, 235.7, IR  $\nu_{\max}^{\text{KBr}}$  (cm<sup>-1</sup>): 3484 (OH), 2936 (saturated C-H), 1452, 1388 (CH<sub>3</sub>), 1090 (C-O). HR-ESI-MS (negative) *m/z*: 541.3892 [M - H]<sup>-</sup> (C<sub>34</sub>H<sub>53</sub>O<sub>5</sub>, calcd. 541.3888). <sup>1</sup>H-NMR (400 MHz, C<sub>5</sub>D<sub>5</sub>N)  $\delta$ : 0.91 (3H, s, 26-CH<sub>3</sub>), 0.97 (3H, s, 25-CH<sub>3</sub>), 1.01 (3H, s, 27-CH<sub>3</sub>), 1.07 (3H, s, 24-CH<sub>3</sub>), 1.33 (3H, s, 23-CH<sub>3</sub>), 0.85 (3H, d, *J* = 6.9 Hz, 29-CH<sub>3</sub>), 0.95 (3H, d, *J* = 6.9 Hz, 30-CH<sub>3</sub>), 3.30 (1H, m, H-3), 5.70 (1H, brs, H-12), 4.79 (1H, d, *J* = 7.0 Hz, Ara-H-1'). The <sup>13</sup>C-NMR spectrum of compound **4** (Table 1) exhibited seven methyl carbons, three quaternary olefinic carbons, one olefinic methine, one oxymethine, and one anomeric carbon. The <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra showed an olefinic proton  $\delta_{\text{H}}$  5.70 (1H, brs, H-12), with four typical olefinic carbon signals at  $\delta_{\text{C}}$  117.4, 137.5, 128.9, and 133.4. By analyzing the 2D NMR spectra, the aglycone of compound **4** was revealed to have a 28-nor-ursane skeleton. HMBC correlations were observed from H-11 to an olefinic methine C-12 and a quaternary olefinic carbon C-13, from Me-27 to a quaternary olefinic carbon C-13, from Me-29 to a quaternary olefinic carbon C-18, as well as from H-15 to a quaternary olefinic carbon C-17. Through analyzing HSQC and HMBC, the hydroxymethine proton was assigned as H-3. NOESY correlation between H-3 and H<sub>3</sub>-23/H-5 indicated the  $\alpha$ -orientation of H-3. Based on the above evidences, the aglycone of compound **4** is elucidated as 3 $\beta$ -hydroxy-28-norurs-12,17-dien, same as compound **2**. The <sup>1</sup>H-NMR spectrum showed one anomeric proton resonating at  $\delta_{\text{H}}$  4.79, which was correlated with carbon at  $\delta_{\text{C}}$  88.7 from the HMQC spectrum. The <sup>13</sup>C-NMR spectrum showed a difference between compounds **2** and **4** and the C-3 signal of compound **4** shifted from  $\delta$  78.2 to  $\delta$  88.7. HMBC correlations were also observed


from an anomeric proton Ara-H-1' to the oxymethine carbon C-3. The coupling constant of Ara-H-1' (d,  $J = 2.0$  Hz) confirmed the  $\alpha$ -glycosidic linkage for the *L*-arabinose units. The  $^{13}\text{C}$ -NMR spectrum confirmed the *L*-arabinose was  $\alpha$ -*L*-arabinopyranoside. After acid hydrolysis, the sugar units were confirmed to be *L*-arabinose by GC analysis. Therefore, compound **4** was assigned as  $3\beta$ -[( $\alpha$ -*L*-arabinopyranosyl) oxy]-28-norurs-12,17-dien. It is a new compound named as

sanguisorbin  $\text{Y}_2$  (Fig. 1).

Compound **5**: white powder (EtOAc). The positive ESI-MS exhibited  $[\text{M} + \text{Na}]^+$  at  $m/z$  495.1, exhibited  $[\text{M} - \text{H}]^-$  at  $m/z$  471.1.  $^1\text{H}$ -NMR (600 MHz,  $\text{C}_5\text{D}_5\text{N}$ )  $\delta$ : 1.11 (3H, d,  $J = 6.0$  Hz, 30- $\text{CH}_3$ ), 0.90, 1.02, 1.11, 1.23, 1.45, 1.73 (18H, s,  $6 \times \text{CH}_3$ ), 3.06 (1H, brs, H-18), 3.43 (1H, m, H-3), 5.61 (1H, brs, H-12). The spectrum data were in accordance with those of pomolic acid (Ju *et al.*, 2003).

**Table 1**  $^{13}\text{C}$ -NMR (100 MHz) spectral data of compounds **1**–**4** ( $\text{C}_5\text{D}_5\text{N}$ ,  $\delta$ )

Positions	1	2	3	4	Positions	1	2	3	4
1	39.3	39.4	39.1	39.2	19	135.9	32.4	32.4	32.3
2	28.4	28.2	27.4	27.4	20	134.8	33.0	33.0	33.0
3	78.1	78.2	87.3	88.7	21	127.0	24.9	24.9	24.9
4	39.6	39.5	39.3	39.6	22	126.3	32.3	32.3	32.3
5	56.3	56.1	56.1	56.1	23	28.6	28.8	28.6	28.6
6	18.9	18.9	18.7	18.6	24	16.3	16.6	17.0	17.0
7	34.2	34.4	34.3	34.3	25	16.9	16.3	16.2	16.2
8	41.3	39.1	39.0	39.0	26	16.0	17.2	17.1	17.1
9	41.8	47.8	47.7	47.7	27	17.2	20.9	20.8	20.8
10	37.6	37.3	37.0	37.0	28	—	—	—	—
11	22.1	23.9	23.9	23.9	29	19.2	13.4	13.4	13.4
12	26.9	117.5	117.4	117.4	30	20.7	19.8	19.8	19.8
13	41.6	137.6	137.6	137.5	3- <i>O</i> -Ara				
14	52.1	41.1	41.1	41.0	1'			111.9	107.5
15	29.0	27.4	26.5	26.8	2'			84.0	73.0
16	28.3	28.6	28.2	28.2	3'			78.8	74.7
17	136.0	128.9	128.9	128.9	4'			85.3	69.5
18	140.0	133.5	133.5	133.4	5'			62.9	66.7



**Fig. 1** Key HMBC correlations of compounds **1**, **3**, and **4**

## References

- Dai YP, Sun LL, Xia HM, Shi DH, Zhou Q, 2011. Determination of sanguisorbigenin Z in different processing grade carbonized *Sanguisorba officinalis* by HPLC. *Chin Pharm J* 46(5): 395-396.
- Guo SY, Jia LY, Xu MS, 2001. Study on hemostatic effect of *Sanguisorbae Radix* and charred *Sanguisorbae Radix*. *Acta Chin Med Pharmacol* 29(4): 28.
- Ju JH, Zhou L, Lin G, Liu D, Wang LW, Yang JS, 2003. Studies on constituents of trierpene acids from *Eriobotrya japonica* and their anti-inflammatory and antitusive effects. *Chin Pharm J* 38(10): 752-757.
- The Traditional Chinese Medicine Preparation Standards*, 1988. Beijing. Pharmacopoeia Committee of P. R. China, 2010. *Pharmacopoeia of People's Republic of China*. China Medical Science and Technology Press: Beijing.
- Sun LL, Yang SB, Li Q, Dai YP, Zhong Y, Sun JY, Xia HM, 2011a. Medicine for treating breast cancer with carbonized *Sanguisorba officinalis* extract as effective component and its preparation method: China, CN 102008496 A 20110413.
- Sun LL, Zhong Y, Yang SB, Shi DH, Lu J, Sun JY, Zhou Q, 2011b. Drug for treating breast cancer and its preparation method: China, CN 102000099 A 20110406.
- Xia HM, Sun LL, Sun JY, Zhong Y, 2010a. Study on chemical constituents of charred *Radix Sanguisorbae* (I). *Food Drug* 12(1): 42-44.
- Xia HM, Zhong Y, Sun LL, Sun JY, Sun LL, An K, Wang J, 2010b. Chemical constituents of charred *Radix Sanguisorbae* (II). *Chin Tradit Herb Drugs* 41(7): 1048-1052.